| Literature DB >> 33717086 |
Weidong Zhang1,2, Ling Gao1,3, Wenhao Ren1, Shaoming Li1, Jingjing Zheng3,4, Shasha Li5, Chunmiao Jiang6, Shuying Yang7, Keqian Zhi1,3.
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug effect. There are multiple hypotheses to explain the development of MRONJ. Reduced bone remodeling and infection or inflammation are considered central to the pathogenesis of MRONJ. In recent years, increasing evidence has shown that bisphosphonates (BPs)-mediated immunity dysfunction is associated with the pathophysiology of MRONJ. In a healthy state, mucosal immunity provides the first line of protection against pathogens and oral mucosal immune cells defense against potentially invading pathogens by mediating the generation of protective immunoinflammatory responses. In addition, the immune system takes part in the process of bone remodeling and tissue repair. However, the treatment of BPs disturbs the mucosal and osteo immune homeostasis and thus impairs the body's ability to resist infection and repair from injury, thereby adding to the development of MRONJ. Here, we present the current knowledge about immunity dysfunction to shed light on the role of local immune disorder in the development of MRONJ.Entities:
Keywords: bisphosphonates; immunity; inflammation; jaw; osteonecrosis
Mesh:
Substances:
Year: 2021 PMID: 33717086 PMCID: PMC7947359 DOI: 10.3389/fimmu.2021.606043
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561